Cardiac abnormalities in patients with mitochondrial DNA mutation 3243A>G by Majamaa-Voltti, Kirsi et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Cardiovascular Disorders
BMC Cardiovascular Disorders  2002,  2 x Research article
Cardiac abnormalities in patients with mitochondrial DNA 
mutation 3243A>G
Kirsi Majamaa-Voltti1, Keijo Peuhkurinen2, Marja-Leena Kortelainen3, 
Ilmo E Hassinen4 and Kari Majamaa*4,5,6
Address: 1Department of Internal Medicine, University of Oulu, Oulu, Finland, 2Department of Internal Medicine, University of Kuopio, Kuopio, 
Finland, 3Department of Forensic Medicine, University of Oulu, Oulu, Finland, 4Department of Medical Biochemistry and Molecular Biology, 
University of Oulu, Oulu, Finland, 5Department of Neurology, University of Oulu, Oulu, Finland and 6Biocenter, University of Oulu, Oulu, 
Finland
E-mail: Kirsi Majamaa-Voltti - kirsi.majamaa-voltti@oulu.fi; Keijo Peuhkurinen - keijo.peuhkurinen@kuh.fi; Marja-Leena Kortelainen - marja-
leena.kortelainen@oulu.fi; Ilmo E Hassinen - ilmo.hassinen@oulu.fi; Kari Majamaa* - kari.majamaa@oulu.fi
*Corresponding author
Abstract
Background: Tissues that depend on aerobic energy metabolism suffer most in diseases caused
by mutations in mitochondrial DNA (mtDNA). Cardiac abnormalities have been described in many
cases, but their frequency and clinical spectrum among patients with mtDNA mutations is
unknown.
Methods: Thirty-nine patients with the 3243A>G mtDNA mutation were examined, methods
used included clinical evaluation, electrocardiogram, Holter recording and echocardiography.
Autopsy reports on 17 deceased subjects were also reviewed. The degree of 3243A>G mutation
heteroplasmy was determined using an Apa I restriction fragment analysis. Better hearing level
(BEHL0.5–4 kHz) was used as a measure of the clinical severity of disease.
Results:  Left ventricular hypertrophy (LVH) was diagnosed in 19 patients (56%) by
echocardiography and in six controls (15%) giving an odds ratio of 7.5 (95% confidence interval;
1.74–67). The dimensions of the left ventricle suggested a concentric hypertrophy. Left ventricular
systolic or diastolic dysfunction was observed in 11 patients. Holter recording revealed frequent
ventricular extrasystoles (>10/h) in five patients. Patients with LVH differed significantly from those
without LVH in BEHL0.5–4 kHz, whereas the contribution of age or the degree of the mutant
heteroplasmy in skeletal muscle to the risk of LVH was less remarkable.
Conclusions: Structural and functional abnormalities of the heart were common in patients with
3243A>G. The risk of LVH was related to the clinical severity of the phenotype, and to a lesser
degree to age, suggesting that patients presenting with any symptoms from the mutation should
also be evaluated for cardiac abnormalities.
Background
Mitochondrial diseases form a heterogeneous group of
disorders with defects in mitochondrial oxidative phos-
phorylation. The majority of these diseases is caused by
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mutations in mitochondrial DNA (mtDNA) [1]. MtDNA
encodes 13 out of more than 80 polypeptides in the mito-
chondrial respiratory chain complexes, and the ribosomal
RNA and transfer RNA necessary for translation in mito-
chondria [2]. The clinical variability of these disorders is
partly due to the fact that all organs may be affected, al-
though those with a high energy expenditure suffer most,
e.g. brain, skeletal muscle and cardiac muscle. Further-
more, the mutant genome may coexist with the wild-type
genome, and the degree of this heteroplasmy partly deter-
mines the clinical phenotype as those organs with a high
proportion of the mutant genome tend to be more severe-
ly affected [3].
Cardiomyopathy is one of the clinical phenotypes associ-
ated with mtDNA mutations [4–7]. Patients with mtDNA
deletions, presenting with the phenotype of the Kearns-
Sayre syndrome, chronic progressive external ophthalmo-
plegia or the Pearson's syndrome, often develop conduc-
tion defects [6], but dilated cardiomyopathy leading to
heart failure has also occasionally been reported [8]. Sev-
eral point mutations of mtDNA have been described in
patients with cardiomyopathy including mutations in the
genes coding for tRNALeu[4,5], tRNAIle[9], tRNALys[6],
tRNAGly[10], 12S rRNA [11] and certain structural genes
[7]. Most commonly, the cardiomyopathy associated with
these mutations is hypertrophic. In addition, multiple
mtDNA deletions with autosomal dominant inheritance
may present with cardiomyopathy [12].
Mitochondrial encephalomyopathy, lactic acidosis and
stroke-like episodes (MELAS) is a distinct clinical syn-
drome characterized by short stature, seizures, hemipare-
sis, hemianopia and cortical blindness [13]. The
syndrome is genetically heterogenous, but approximately
80% of the patients with the MELAS syndrome harbor a
heteroplasmic A-to-G transition in the tRNALeu at base
pair 3243 in mtDNA (3243A>G) [14]. Cardiomyopathy
has been described in patients with the 3243A>G muta-
tion [5,6,15], but the frequency and the degree of severity
of the cardiac manifestations has remained obscure as the
earlier reports have been based on studies of small
number of selected patients. Therefore, we set out to
search for the frequency and quality of cardiac abnormal-
ities among 52 members from 13 families with the
3243A>G mutation. The families have been ascertained in
a well-defined population and represent a good approxi-
mation of a population-based cohort of patients with the
mutation [16].
Methods
Patients
We have previously ascertained 11 pedigrees with the
3243A>G mutation in the population of the province of
Northern Ostrobothnia in Finland [16] and two addition-
al pedigrees have been ascertained in the population of
the province of Central Ostrobothnia. Persons that had
reached the age of 18 years and belonged to the sibship of
the proband or to the sibship of proband's mother were
considered for the study. Eligible persons had been shown
to be carriers of 3243A>G mutation or were first-degree
maternal relatives to a verified mutation carrier. The latter
persons are considered obligatory carriers of the mutation
and they harbor the mutation with a high probability
[17]. Cardiological evaluation was performed on 35 veri-
fied 3243A>G carriers and 13 verified or obligatory carri-
ers were studied by review of autopsy reports. Both clinical
data and autopsy data were available from four additional
subjects with the 3243A>G mutation. Better ear hearing
level (BEHL0.5–4 kHz), calculated as the mean of the hear-
ing levels over the frequencies of 0.5, 1, 2 and 4 kHz, was
used as a measure of the clinical severity of disease caused
by 3243A>G [18]. Twenty patients had diabetes mellitus
that was considered to be caused by the 3243A>G muta-
tion in each case. A causal relationship was assumed if
three of the following four criteria were fulfilled: progres-
sive insulin secretory defect, lack of islet cell antibodies,
low body mass index and onset at early adulthood [19].
Controls
Each patient with 3243A>G mutation was matched with
respect to age, sex and diagnosis of hypertension with a
control that was chosen from a population-based cohort
of 1200 persons. This cohort includes 600 patients with
an anti-hypertensive medication and 600 nonhyperten-
sive subjects [20]. For 14 patients with 3243A>G muta-
tion that were under 40 years old, a matched control was
chosen from echocardiographic registry at the Cardiologic
Department in Oulu University Hospital. The controls
had been examined because of palpitation, short of breath
or suspicion of genetic aortic disease and after cardiologic
evaluation they had been deemed healthy. Diabetes is a
common phenotype associated with the 3243A>G muta-
tion and presents with features that differ from those in
type I and type II diabetes mellitus [19]. Therefore, match-
ing of cases and controls with respect to diabetes mellitus
was not attempted.
The study was approved by the Ethical Committee of the
Medical Faculty at the University of Oulu and the clinical
examinations were carried out with the informed consent
from the patient.
Cardiac examinations
Twelve-lead ECGs were obtained in 39 patients, and these
were interpreted according to standard criteria. Left ven-
tricular hypertrophy (LVH) was diagnosed, whenever R in
V5 or V6 + S in V1 exceeded 4.5 mV [21]. Echocardiogra-
phy was performed in 35 patients, and the measurements
were obtained and interpreted according to the standardsBMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/12
Page 3 of 7
(page number not for citation purposes)
of the American Society of Echocardiography (ASE) [22].
The left ventricular volumes and ejection fraction were
calculated using the method of Teichholz. Left ventricular
function was evaluated using also 2-dimensional echocar-
diography and visual interpretation. LVH was diagnosed
by left ventricular wall thickness when interventricular or
posterior wall diastolic thickness exceeded 12 mm in non-
hypertensive and 14 mm in hypertensive patients [23].
Left ventricular mass (LVM) was calculated from the ASE
measurements according to the corrected equation [24]
and it was related to body surface area. The cut-off points
for left ventricular hypertrophy by left ventricular mass-in-
dex (LVMI) were 134 g/m2 for men and 110 g/m2 for
women [25]. The mitral inflow velocity was measured by
pulsed-wave Doppler echocardiography in the apical
four-chamber view. Peak early diastolic and peak late di-
astolic velocities were measured and E/A max ratios were
used when evaluating diastolic function of the left ventri-
cle. Regurgitation of valves was estimated with pulsed-
wave or color Doppler echocardiography.
Thirty-six patients underwent standard 24-hour Holter
monitoring. Four patients were catheterized, one for chest
pain and LVH, one for congestive cardiomyopathy, one
for LVH and unexpected pulmonary oedema and one for
asymptomatic paroxysmal Mobitz type II AV-block ob-
served during the Holter monitoring.
Review of autopsy reports
Autopsy had been performed on 17 cases and the weight
of the heart had been documented in 12 autopsies. In the
remaining reports the heart was stated to be normal in size
in four cases and in one report the heart was described as
hypertrophic. Body length was recorded in all autopsy re-
ports. In none of the autopsies chamber partition had
been made, but the total heart weight is known to provide
a good approximation of left ventricular hypertrophy
[26]. Cardiac hypertrophy was diagnosed if the heart
weight of the patient was one standard deviation greater
than the mean weight of the normal heart stratified by sex
and body length [27].
Mitochondrial DNA analysis
Muscle biopsy specimens were obtained from 33 patients
with 3243A>G from the anterior tibial muscle or vastus
lateralis of the quadriceps muscle, right ventricular en-
domyocardial biopsies were obtained from four patients
during catheterisation, and myocardial samples were ob-
tained from six patients at autopsy. Total DNA was isolat-
ed from tissue samples by the standard SDS-proteinase K
method. The 3243A>G mutation was determined using
an Apa I restriction digestion of a 390 bp mtDNA frag-
ment (from nt 3150 to nt 3550) amplified by PCR in the
presence of 35S-ATP [28]. The fragments were electro-
phoresed through a 6% nondenaturating polyacrylamide
gel, which was then dried and autoradiographed at -72°C
overnight using Kodak XAR film with an intensifying
screen. Films were analyzed with a Bioimage scanner and
image processing apparatus (Millipore, Ann Arbor, MI).
Statistical analysis
The Mann-Whitney U test was used to detect difference
between two groups and Kruskall-Wallis test between sev-
eral groups. The Wilcoxon signed rank test and the McNe-
mar test were used when comparing paired data.
Results
Clinical features of the patients
Thirty-nine patients with the 3243A>G mutation (15
men, 24 women; mean age 48 ± 13 years) were clinically
studied for cardiac abnormalities. Twenty of them were
diabetic, but none of them had diabetic nephropathy. The
cardiovascular history was uneventful in 27 patients,
while the remaining patients reported chest pain (n = 7),
hypertension (n = 7), coronary artery disease (n = 6) that
had required by-pass surgery in two patients and dyspnea
(n = 5). The physical examination was normal in most pa-
tients, but auscultation revealed systolic murmurs in five
and gallops in three patients. Elevated central venous
pressure was observed in two patients. Resting ECG re-
vealed conduction abnormalities in five patients (abnor-
mally short PQ time, 2; 1° AV block, 1; bundle branch
blocks, 2). Two patients had sinustachycardia at rest with
heart rate exceeding 100 bpm.
Left ventricular hypertrophy
Echocardiography was performed on 34 patients with
3243A>G and 34 controls that were matched with respect
to age, sex and the diagnosis of hypertension (Table 1).
Echocardiography revealed an increased ventricular wall
thickness suggesting LVH in 19 patients (56%; 95% con-
fidence interval (CI); 38 – 73%) and in six controls (15%;
95% CI; 6 – 31%) giving an odds ratio of 7.5 (95% CI;
1.74 – 67). The median left ventricular septal or posterior
wall end-diastolic thickness was 14 mm (range 12 – 23
mm) in the patients with LVH (Table 1). The thickness of
the left ventricular septum and posterior wall was signifi-
cantly greater and the left ventricular end-diastolic diame-
ter was significantly smaller in the patients than in the
controls suggesting concentric hypertrophy (Table 1).
Systolic dysfunction was diagnosed in four patients with
LVH, whereas abnormal left ventricular filling patterns
and thus signs of diastolic dysfunction were observed in
five patients (Table 2).
The ratio of left ventricular mass to body surface area (LV-
MI) could be calculated for 28 patients with the 3243A>G
mutation. The mean LVMI was slightly but not significant-
ly higher in the patients than in the controls. If cut-off
points over 134 g/m2 for men and 110 g/m2 for womenBMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/12
Page 4 of 7
(page number not for citation purposes)
were used to diagnose left ventricular hypertrophy, the pa-
tients with the 3243A>G mutation had significantly more
LVH than the controls (Table 1).
Thirty-two members in the sibships had died and an au-
topsy had been performed on 17 of them including four
patients that had been examined clinically during life. The
review of the autopsy reports revealed nine patients with
LVH giving a frequency of 53%. The median heart weight
in these patients was 472 g (range 322 – 570 g). Altogeth-
er, we found 26 patients with LVH among the 47 patients
studied suggesting a total frequency of 55% (95% CI; 40
– 69%) for LVH in the clinical study cohort and the autop-
sy cohort.
Factors contributing to cardiac hypertrophy
There was no difference in sex distribution or frequency of
diabetes mellitus between the patients with LVH and pa-
tients without LVH. The mean age of the patients with
LVH was slightly higher than that of the patients without
LVH (Table 3) and a contribution of age was also suggest-
ed by autopsy data as the mean age at death of the patients
with LVH, 59 ± 15 years, was significantly higher than the
age, 38 ± 10 years, of the patients that died without LVH
(p = 0.004). The severity of disease measured by BEHL0.5–
4 kHz was significantly higher among patients with LVH.
Three patients had suffered from stroke-like episodes, two
of whom had LVH.
The degree of the 3243A>G mutation heteroplasmy was
determined in skeletal muscle of 33 out of the 39 patients
Table 1: Comparison of the patients with the 3243A> G mutation and the matched controls.
Patients with 3243A>G Controls p-value
Gender (% men) 38.5 38.5 1.00
Age (yrs) 46.7 ± 12.7 46.8 ± 11.5 0.63
Hypertension (n) 10 10 1.00
Diabetes mellitus (n) 20 7 0.001
Left ventricular dimensions
ST(D) (mm) 12.2 ± 3.2 10.0 ± 1.7 0.003
PWT(D) (mm) 12.1 ± 3.7 10.0 ± 1.8 0.02
LVD(D) (mm) 43.4 ± 5.8 49.6 ± 5.4 <0.001
LVH* (n) 19 6 0.002
Left ventricular mass
LVMI (g/m2) 127 ± 54 102 ± 24 0.06
LVH† (n) 12 3 0.02
ST(D), thickness of interventricular septum in diastole; PWT(D), thickness of posterior ventricular wall in diastole; LVD(D), left ventricular end-
diastolic diameter; LVH*, left ventricular hypertrophy = septal or posterior wall end-diastolic thickness ≥  12 mm in non-hypertensives and ≥  14 mm 
in medically treated hypertensives [23]; LVMI, left ventricular mass/body surface area, where LVM is left ventricular mass calculated by the method 
of American Society of Echocardiography: 0.8 ×  (1.04 ×  ((LVID/10 + IVS/10 + PVW/10)3 – (LVID/10)3) + 0.6 [24,25]; LVH†, left ventricular hyper-
trophy = LVMI over 134 g/m2 for men and 110 g/m2 for women [25]. Values are means ± standard deviations.
Table 2: Findings at cardiac examination of the patients with the 
3243A>G mutation.
Patients (n)
ECG
Normal 22
LVH 9
Conduction disturbances 5
Other* 9
Echocardiography
Normal 16
LVH 19
LVSD or LVDD 9
Valvular disorders 6
Holter-recordings
Normal 14
Benign extrasystoles† 15
VES >30/h 1
SVT/AF attacks 4
NSVT 1
Conduction disturbances‡ 4
LVH, left ventricular hypertrophy; LVSD, left ventricular systolic dys-
function; LVDD, left ventricular diastolic dysfunction; VES, ventricular 
extrasystoles; SVT, supraventricular tachycardia; AF, atrial fibrillation; 
NSVT, non-sustained ventricular tachycardia. LVSD was diagnosed if 
ejection fraction < 50%. LVDD was diagnosed if E/A-ratio < 1. *Other 
ECG findings include: Q-wave abnormalities, 2; ST/T-wave abnormali-
ties, 4; sinustachycardia, 2; prolonged QTc, 1.†Supraventricular extra-
systoles or VES <30/h. ‡Conduction disturbances include: Mobitz II 
AV-block, 1; intermittent delta wave, 1; sinus arrests (2.4–2.8 s), 2.BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/12
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that were clinically examined. The degree of the mutant
heteroplasmy did not differ between patients with LVH
and patients without LVH, but among the patients with
LVH we found a linear correlation between the degree of
the mutant heteroplasmy and LVMI (Pearson correlation
coefficient 0.641, p = 0.034). Furthermore, the degree of
the mutant heteroplasmy was 81% (range; 72 – 89%) in
endomyocardial samples from four patients, two of
whom were diagnosed with LVH, and 75% (range; 57 –
81%) in cardiac muscle samples obtained at autopsy from
six patients, three of whom had LVH. Samples from both
skeletal muscle and endomyocardium or postmortem
myocardium were available from seven patients. The
mean degree of the heteroplasmy of the 3243A>G muta-
tion in the skeletal muscle was 78 ± 7% and that in cardiac
muscle 81 ± 7% (p = 0.40; Wilcoxon test).
Arrhythmias and conduction disturbances
Holter monitoring was accomplished in 36 patients. Clin-
ically significant arrhythmias or conduction disturbances
were found in 10 patients suggesting a frequency of 28%
(Table 2). Five patients presented with > 10 ventricular ex-
trasystoles/hour. The highest frequency of ventricular ex-
trasystoles (2700/24 hours) with episodes of bigeminy
and trigeminy was observed in the only patient with con-
gestive cardiomyopathy. Episodes of non-sustained ven-
tricular tachycardia were observed in one patient with
LVH, and asymptomatic sinus arrest in two patients with
LVH. One patient without LVH had asymptomatic Mobitz
type II AV-block and one patient with LVH was diagnosed
to have WPW syndrome on the basis of intermittent delta-
wave and SVT attacks during Holter monitoring. Three pa-
tients with LVH had episodes of atrial fibrillation that
were symptomless.
Discussion
Our extensive screening of a defined population in north-
ern Finland for the 3243A>G mtDNA mutation has yield-
ed a good approximation of a population-based cohort of
patients with this mutation [16]. In the present study we
examined complete sibships from 11 pedigrees ascer-
tained in the screening as well as two additional pedigrees
from a neighboring province, where the prevalence of the
mutation appears to be similar to that observed in the
original ascertainment population. We found that LVH
was the most common cardiac abnormality in pedigrees
with the 3243A>G mtDNA mutation. LVH was diagnosed
in 19 out of 34 patients by echocardiography and in nine
out of 17 patients in autopsy suggesting an overall fre-
quency of 55% among verified or obligatory carriers of the
mutation. Furthermore, comparison of the patients with
the 3243A>G mutation with matched controls revealed
that the odds ratio of LVH was 7.5.
Clinically defined cardiomyopathy has been reported
among patients with various other mtDNA point muta-
tions and these case reports suggest that LVH is more com-
mon than cardiac dilatation in mitochondrial diseases
[7]. We found that the 3243A>G mutation was almost ex-
clusively associated with LVH, as we observed 26 patients
with LVH but only one patient with congestive cardiomy-
opathy without LVH in the clinical study and one patient
with cardiac dilatation in the review of the autopsy re-
ports. Interestingly, knock-out mice with inactivated mi-
tochondrial adenine nucleotide translocator develop
hypertrophic cardiomyopathy [29] suggesting that cyto-
plasmic ATP deficiency is an essential contributor to the
pathogenesis of this condition. Indeed, a role for ATP de-
ficiency in patients with 3243A>G can be further inferred
from studies on cultured myoblasts harboring 3243A>G
that show a decreased concentration of ATP [30]. On the
other hand, dilated cardiomyopathy is a rare phenotype
of the 3243A>G mutation [15]. Dilated cardiomyopathy
develops in mutant mice lacking manganese superoxide
dismutase [31] suggesting that the increased oxidative
stress may have a role in the pathogenesis of this condi-
tion. However, the pathogenetic cascade in cardiomyopa-
thy may also include other events related to
mitochondria, such as disturbance of calcium homeosta-
sis or apoptosis.
Cardiac conduction abnormalities are common in the
Kearns-Sayre syndrome and include prolonged intraven-
tricular conduction time, bundle branch blocks and com-
Table 3: Comparison of patients with and without LVH.
Patients with LVH Patients without LVH p Value
Men/women (n) 9/10 6/14 0.33
Age (years) 53 (26 – 69) 45 (22 – 65) 0.28
Mutant heteroplasmy in muscle (%) 73 (48 – 83) 64 (30 – 91) 0.34
BEHL0.5 kHz-4 kHz (dB) 53 (0 – 103) 29 (0 – 64) 0.022
LVH was diagnosed if septal or posterior wall end-diastolic thickness ≥  12 mm in non-hypertensives and ≥  14 mm in medically treated hypertensives 
[23]. BEHL0.5–4 kHz, better ear hearing level over the frequencies 0.5 kHz, 1 kHz, 2 kHz and 4 kHz. The values are medians (range)BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/12
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plete AV conduction block [32]. We found some patients
with abnormalities in impulse formation or conduction,
and most often these were associated with LVH. An inter-
mittent delta wave suggesting pre-excitation was found in
one patient with LVH, an observation reported also earlier
in patients with the 3243A>G mutation [33]. Many stud-
ies have clearly demonstrated that LVH is an important
predictor of cardiovascular events and mortality [34]. LVH
is a forerunner of coronary artery disease, cardiac failure,
stroke and peripheral artery disease, and it is associated
with ventricular arrhythmias potentially leading to sud-
den cardiac death even in the absence of clinically signifi-
cant coronary artery disease [35]. We found functional
abnormalities, defined as the presence of significant ven-
tricular arrhythmias or left ventricular dysfunction, in the
majority of the LVH patients. Therefore, cardiac evalua-
tion of patients with 3243A>G seems worthwhile as an as-
sessment of the risk of these lifethreatening events.
The relative amount of the mutant genome in tissues is
one factor affecting the biochemical phenotype of mtDNA
diseases, although nuclear modulatory factors, synergistic
mtDNA mutations and mtDNA copy number may also
contribute [36]. Furthermore, the clinical phenotype is
modulated by an imbalance between the energy demand
and energy supply of a given tissue and by environmental
or physiological factors, such as aging [37]. We found that
the risk of LVH was substantially increased among pa-
tients with the 3243A>G mutation compared to controls
suggesting a role for the mutation itself. No contribution
could be assigned to gender or diabetes mellitus, but high-
er age and more severe clinical phenotype were associated
with the risk of LVH. Interestingly, there was no clear dif-
ference in the proportion of the mutant genome between
patients with LVH and patients without LVH suggesting
that estimation of the risk of LVH cannot solely be based
on the degree of mutant heteroplasmy in muscle. Howev-
er, among patients with LVH a significant correlation was
observed between LVMI and the degree of the mutation
heteroplasmy. We found that there was no difference in
the degree of mutant heteroplasmy in skeletal and cardiac
muscle suggesting that the degree of mutant heteroplasmy
in skeletal muscle may be used as an estimate of that in
the cardiac muscle.
The frequency of mtDNA mutations among unselected
patients with hypertrophic or dilated cardiomyopathy is
unknown. Although the 3243A>G mutation is probably
the most common pathogenic mutation in mtDNA [16],
and although the frequency of cardiomyopathy in pa-
tients with this mutation is fairly high, there are many oth-
er mtDNA mutations that have been reported to cause
hypertrophic or dilated cardiomyopathy [38]. Many of
these mutations cluster either in the gene for leu-
cine(UUR)-tRNA or isoleucine-tRNA, but some mutations
have been found in genes coding for the subunits of the
respiratory chain. The clinical phenotypes caused by these
mutations are very variable ranging from fatal infantile
cardiomyopathy to mildly symptomatic adult onset cardi-
omyopathies. Most of these mutations have been detected
only in single patients or families, and currently their sig-
nificance in the clinical diagnostics is not known. Howev-
er, the total frequency of various mtDNA mutations in
patients with cardiomyopathy may be high enough to jus-
tify efforts for specific diagnosis, at least in patients with
familial cardiomyopathy or with multiorgan syndrome
involving cardiomyopathy.
Conclusion
Our results indicate that patients with the 3243A>G mtD-
NA mutation bear a considerable risk for cardiac patholo-
gy and, therefore, these patients should be evaluated for
cardiac abnormalities, especially if other clinical manifes-
tations from the mutation are present.
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